Category Archives: Stem Cell Clinic


Documenting THE CURE: Seeking Stem Cell Healing Offshore — MS patient – Video

13-02-2012 21:11 Documenting THE CURE is a funding project to write a book about patients leaving the US to receive natural healing Stem Cell treatments in Panama. DONATE: http://www.kickstarter.com The FDA ban on all stem cell treatments forces Americans to seek adult (non-embryonic) stem cell treatments offshore. This new type of stem cell treatment is documented in Dr. Roger Nocera's new book, Cells That Heal Us From Cradle To Grave: A Quantum Leap in Medical Science. JL Thompson will document the effectiveness of this treatment on an MS patient, and other patients seeking treatment at the Panama clinic.

Read more:
Documenting THE CURE: Seeking Stem Cell Healing Offshore -- MS patient - Video

UQ researchers make breakthrough in stem cell research

University of Queensland scientists have developed a world-first method for producing adult stem cells that will substantially impact patients who have a range of serious diseases.

The research is a collaborative effort involving UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and is led by UQ Clinical Research Centre's (UQCCR) Professor Nicholas Fisk.

It revealed a new method to create mesenchymal stem cells (MSCs), which can be used to repair bone and potentially other organs.

?We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature,? Professor Fisk said.

?The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

?To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumours.

?Because only small numbers of MSCs exist in the bone marrow and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

?We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

AIBN Associate Professor and Co-Investigator on the project, Ernst Wolvetang said the new protocol had overcome a significant barrier in the translation of stem cell-based therapy.

?We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN,? Associate Professor Wolvetang said.

The research is published in the February edition of the STEM CELLS Translational Medicine journal.

UniQuest, The University of Queensland's main commercialisation company, invites parties interested in licensing the intellectual property relating to this discovery to contact UniQuest on 3365 4037 or lifesciences@uniquest.com.au.

Media Contact: Kirsten Rogan, Communications and Media, University of Queensland Faculty of Health Sciences, 07 3346 5308, 0412307594 or k.rogan@uq.edu.au

The rest is here:
UQ researchers make breakthrough in stem cell research

Researchers make breakthrough in stem cell research

The research is a collaborative effort involving UQ's Australian Institute for Bioengineering and Nanotechnology (AIBN) and is led by UQ Clinical Research Centre's (UQCCR) Professor Nicholas Fisk.

It revealed a new method to create mesenchymal stem cells (MSCs), which can be used to repair bone and potentially other organs.

“We used a small molecule to induce embryonic stem cells over a 10 day period, which is much faster than other studies reported in the literature,” Professor Fisk said.

“The technique also worked on their less contentious counterparts, induced pluripotent stem cells.

“To make the pluripotent mature stem cells useful in the clinic, they have to be told what type of cell they need to become (pre-differentiated), before being administered to an injured organ, or otherwise they could form tumours.

“Because only small numbers of MSCs exist in the bone marrow and harvesting bone marrow from a healthy donor is an invasive procedure, the ability to make our own MSCs in large number in the laboratory is an exciting step in the future widespread clinical use of MSCs.

“We were able to show these new forms of stem cells exhibited all the characteristics of bone marrow stem cells and we are currently examining their bone repair capability."

AIBN Associate Professor and Co-Investigator on the project, Ernst Wolvetang said the new protocol had overcome a significant barrier in the translation of stem cell-based therapy.

“We are very excited by this research, which has brought together stem cell researchers from two of the major UQ research hubs UQCCR and AIBN,” Associate Professor Wolvetang said.

The research is published in the February edition of the STEM CELLS Translational Medicine journal.

Provided by University of Queensland (news : web)

Read more:
Researchers make breakthrough in stem cell research

$30 million donation from Boris family will help McMaster turn stem cell research into therapy

McMaster University is on its way to moving stem cell research “from the bench to the bedside” thanks to a $30 million boost from a local family.

The Marta and Owen Boris Foundation made the large donation to establish a human stem cell therapy centre and a unique clinic for patients with complex health conditions.

Owen, the founder of Mountain Cablevision, was in talks with McMaster about investing in their work before he died last April. His children and wife contacted the university a month later and carried out his vision, firming up their commitment last November.

The Boris Family Centre in Human Stem Cell Therapies will be developed as part of the McMaster Stem Cell and Cancer Research Institute using $24 million of the funds.

“It’s getting over that chasm from the bench to the bedside that this (donation) is going to allow us to do,” the institute’s scientific director Dr. Mick Bhatia said.

The centre will give scientists the resources to focus on converting McMaster’s breakthroughs — such as the ability to make blood or types of neural cells with stem cells — into clinical applications through investigative trials, Bhatia said.

“In the absence of this donation, I think we would not be in the position to move our discoveries forward,” he said. “This is a huge leg-up. I’m hoping what it’s really going to do is have a ripple effect to change the way McMaster views translating basic science.”

They plan on developing human stem cell therapies targeting leukemia and possibly neural diseases such as Alzheimer’s and Parkinson’s, said Dr. John Kelton, dean and vice-president of the faculty of health sciences.

The remaining $6 million will go toward building a clinic in partnership with Hamilton Health Sciences (HHS) where patients with complex health issues can see specialists and undergo tests in one visit.

This was a result of his parents’ frustrating experiences in recent years with co-ordinating specialists and getting diagnostic testing done in Canada, said Owen’s son, Les Boris.

They ended up going to Mayo Clinic in Rochester, Minn., where they had a case manager who co-ordinated their appointments with specialists and made sure testing was done in-house, he said. “They like the idea of a one-stop shop … (My father) said: ‘This is the kind of model we need here in this country.’”

Kelton said the medical clinic, which will be built in the university’s medical centre, will look for rapid turnaround times and avoid duplications of lab tests. McMaster and HHS will also evaluate the clinic’s success and keep an electronic medical record that patients could access, he said.

Kelton and Owen met three years ago and had their last meeting about the projects three days before the philanthropist died.

Owen had worked on the Avro Arrow and was frustrated with Canada’s lost opportunity of making jet planes for the world, Kelton said.

“He said, ‘Tell me about some opportunities (that) – if we invested in it – could make Hamilton and McMaster world-class. What are some of the areas like an Avro Arrow?’”

The funds for the human stem cell therapy centre will go toward hiring a research chair in blood stem cells and a research chair in neural stems cells, setting up several fellowships and technician positions, and building the facility.

Bhatia says they hope to bring in new scientists and fellows by the early summer.

The Boris family previously donated $6 million to addiction research at St. Joseph’s Healthcare for its new mental health hospital being built on the Mountain and another $5 million for the da Vinci SI Surgical Robotic System.

“We’re very appreciative that we’re in a position to be doing something for the community,” Les said. “And it was the community that put us in the position to do this.

dawong@thespec.com

905-526-2468 | @WongatTheSpec

Follow this link:
$30 million donation from Boris family will help McMaster turn stem cell research into therapy

From the Avro disappointment to the gift of stem-cell research

Scrapping the nascent all-Canadian Avro Arrow jet fighter program in 1959 is still mourned as a national blunder but, 53 years later, the law of unintended consequences is drawing from it unexpected bounty.

Owen Boris, as a young engineer, was a technically savvy worker who lost his job when the Avro program ended; he returned to Hamilton where he started installing television antennae for neighbours. From there he built a modern high-speed Internet, telephone and cable company that he sold in 2009 for an estimated $300 million.

The businessman did not forget his disappointment with the demise of Avro and never again wanted Canadian innovation to be squandered.

Mr. Boris died suddenly in April at the age of 79 but, on Monday, at a ceremony in Hamilton, his family is announcing a $30-million donation in his name to McMaster University to spur medical research and innovation, primarily in human stem-cell therapies.

“Owen Boris was very frustrated with a couple of things,” said Dr. John Kelton, vice-president of McMaster’s faculty of health sciences and dean of its Michael G. DeGroote School of Medicine.

“He had been involved with the Avro Arrow and many times he said how frustrated he was that Canada was on the edge of having one of the finest aviation machines and it was squandered. He saw it as a failed opportunity for Canada. That bothered him.”

Mr. Boris was also frustrated by Canada’s often cumbersome health-care system. “He went to the Mayo Clinic and wondered why we can’t have something like a Mayo Clinic in Canada,” Dr. Kelton said.

The donation aims to posthumously address both of those frustrations.

Of the donation, $24-million will establish the Boris Family Centre in Human Stem Cell Therapies, designed to speed the commercial development of discoveries, and $6-million will create a special hospital clinic where patients with complex health problems can see several specialists and have related tests during one visit.

“Owen compared stems cells to the Avro Arrow program — he asked why, with all the basic research that’s happening here at McMaster, can we not get it into patients more quickly? If children are dying of leukemia and stem cells might save them, why aren’t we doing it yet?” said Dr. Kelton of his discussions with Mr. Boris shortly before his death.

“And he asked why is it so hard to get health care in Canada that is fast and efficient?”

McMaster University

Owen Boris liked speed in jets, boats and medicine.

Mr. Boris was all about fast and efficient. It was what sparked his love of the Arrow, pushed him to set speed-boat racing records and to build and fly his own plane. It was also a mantra for his business.

Dissatisfied with both the quality and quantity of television reception in the 1950s, he built a television tower in the backyard of his Hamilton home to pull in a better signal and additional channels from Toronto, Buffalo and Cleveland.

When neighbours asked him about it, he dug trenches to bury cables from his tower to their homes to share the signal.

It wasn’t long before providing cable television became his main focus and, under the name Mountain Cable and with the help of his wife, Marta, business roared. Renamed Mountain Cablevision it became one of the largest and most technically advanced independent cable TV providers in Canada.

McMaster University hopes to match Mr. Boris’ passion for speed and success in the medical field through the cash infusion.

“My dad had been to the Mayo Clinic a couple of times and raved about it,” said Les Boris, Mr. Boris’s son. “We’re looking to see that type of model and infrastructure created here, so that people can have access to the best doctors, efficient diagnosis and immediate treatment.”

“Without any wait times,” added his sister, Jackie Work.

In response, the university visited the Mayo Clinic to look for ways to apply its philosophy to Canada’s universal health-care system.

The bulk of the Boris money, however, will boost efforts at the McMaster Stem Cell and Cancer Research Institute, with an eye on moving research out of the lab and into the hospital.

“The Boris family want us to fast track the basic research to get it into patients. They are a family intent on moving things forward and here is a chance to operationalize that,” Dr. Kelton said.

The money will allow the school to recruit top researchers to the six-year-old institute that has already had several breakthroughs, including the ability to turn human skin into blood.

The Boris funds will establish two senior research chairs, one in blood stem cells and the other in neuro stem cells, with $5-million in funding each, the largest at the university.

“That is so large it will let us bring in the top dogs,” Dr. Kelton said. “It gives us a hunting licence to go out and get them and fund the lab and their research.”

The money will also fund several fellowships, technician positions and infrastructure building.

The Boris family has already given away millions.

Last year, the family donated $11-million to Hamilton’s St. Joseph’s Healthcare: $6-million to fund alcohol addiction research in memory of Mr. Boris’s son, Peter, who suffered from alcohol addiction before his death at age 44, and $5-million to buy an advanced robotic surgical system.

Before his death, Mr. Boris gave $3-million to fund a stem-cell vision research position at the Toronto General and Western Hospital Foundation.

“This is a continuation of the gifts that our family has already started giving back to the Hamilton community,” said Ms. Work. Added Les Boris: “We want to give back to the people in this city who supported our business for years.”

National Post
ahumphreys@nationalpost.com

Link:
From the Avro disappointment to the gift of stem-cell research

Bonita stem cell doctor's attorney quits, state hearing still scheduled

Interview with Dr. Zannos Grekos Grekos contests that his office has done ...

The state took action against Dr. Zannos Grekos because of the death of a 69-year-old breast cancer patient April 4, 2010, after undergoing the treatment at his Bonita Springs practice, at 9500 Bonita Beach Road, Suite 310.

BONITA SPRINGS — Dr. Zannos Grekos may not have an attorney representing him at a hearing next month against a state complaint that he performed an unauthorized stem cell procedure on a patient who later died.

Or maybe the Bonita Springs cardiologist will have new counsel for the three-day administrative hearing scheduled to begin March 20.

His original attorney, Greg Chaires of Orlando, withdrew from the case Jan. 24, less than two months before the hearing. He's been Grekos' attorney since the state filed an administrative complaint against the doctor a year ago.

Grekos couldn't be reached for comment at his practice, Regenocyte Therapeutic, 9500 Bonita Beach Road, Suite 310.

Chaires stated in his withdrawal notice to the judge that he had good cause to stop representing him, but didn't elaborate.

Florida health department spokeswoman Jennifer Hirst said this past week that Grekos has two weeks to hire a new attorney "and regardless of whether he does or not, the trial date will not change."

The case, which stems from events in early 2010, culminated a year later on Feb. 22, 2011, when the health department imposed an emergency restriction against his license. The restriction prohibits him from doing any procedures with bone marrow or stem cells in his practice.

If the administrative law judge sides with the state, Grekos could face sanctions or permanent restriction or revocation of his license.

At issue was Grekos' treatment of a 69-year-old woman who went to him for a consult on Feb. 25, 2010, for numbness and tingling in her arms and legs after chemotherapy.

Grekos ordered imaging of her carotid arteries and her brain and later injected her own aspirated bone marrow into her cerebral circulatory system.

At home that evening, she fell and was hospitalized. She had suffered a severe brain stem injury and was taken off life support on April 2, 2010.

Licensed in Florida since 1992, Grekos' cardiology practice in recent years has focused more on stem cell therapy to repair damaged heart muscle, lungs and other tissue.

He sends a sample of a patient's lung to Israel to cultivate new stem cells and the blood gets sent to a clinic or hospital in the Dominican Republic. The patient travels to the Dominican Republic, where the stem cells are injected into the damaged tissue.

Grekos has established a relationship with doctors and clinicians in the Dominican Republic who do the injections on his behalf; he isn't licensed to practice medicine there.

The case has captured widespread attention among Grekos' supporters who swear their once-chronic illnesses have undergone dramatic improvement since having the therapy through him. Detractors say he is taking advantage of a vulnerable population with congestive heart failure, lung failure and other illnesses for which conventional treatments no longer are effective.

See the article here:
Bonita stem cell doctor's attorney quits, state hearing still scheduled

Stoney Creek firm licenses stem cell technology

New York-based IntelliCell BioSciences has licensed its patent-pending technology for the manufacture of stem cells to RegenaStem Inc., based in Stoney Creek. Under the agreement, the company name, RegenaStem, will be changed to IntelliCell BioSciences of Canada. According to company president, Jason Kane, talks are under way with Health Canada to begin manufacturing stem cells and using the technology to treat people with degenerative joint disease, such as arthritis. The treatment is designed to rebuild and repair cartilage and tissue. Clinical trials are set to begin this year. Other applications are also being planned.

Kane’s background in stem cell work includes leading the launch of the first in-clinic stem cell therapy kits for veterinarians in Canada. For more information, call 289-887-5195 or email jkane@intellicellbiosciences.ca

Construction association members honoured

The Hamilton-Halton Construction Association (HHCA) will honour eight of its members for their achievements in health and safety during the association’s annual general meeting next week.

The recipients of the 2011 awards are Comstock Canada, Lancaster Sheet Metal, Barclay Construction, McGowan Insulations, Safway Services Canada, John Kenyon Limited, Brand/Aluma Enterprises and B&G Roofing and Sheet Metal.

Also during the meeting, Ted Wyatt — who has been involved in the local construction industry since the 1950s — will be inducted in to the Construction Hall of Fame. Ron Worrall will receive the Young Leader Award.

The incoming president of the HHCA is Jim DiNovo, president of BML Multi Trades Group Ltd. in Brantford. He takes over for outgoing president Domenic Mattina, vice-president at Mattina Mechanical Limited.

Tricia Hellingman is president of Hellingman Communications, a Hamilton-based public relations and marketing agency. Bizz Buzz welcomes submissions from the business community. Contact thellingman@hellingman.com.

Read the original here:
Stoney Creek firm licenses stem cell technology

StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

NEWARK, Calif., Jan. 30, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM
-
News) today announced the publication of preclinical data
demonstrating that its proprietary HuCNS-SC(R) cells (purified
human neural stem
cells) protect host photoreceptors and preserve vision
in an animal model of retinal disease. The preclinical
results are highly relevant to human disorders of vision loss,
the most notable of which is dry age-related macular degeneration
(AMD). The study is available online at
http://onlinelibrary.wiley.com/doi/10.1111/j.1460-9568.2011.07970.x/abstract
and will be featured as the cover article in the February issue
of the international peer-reviewed European Journal of
Neuroscience.

This research was conducted in collaboration with a team of
researchers led by Raymond Lund, Ph.D., Professor Emeritus of
Ophthalmology, and Trevor McGill, Ph.D., Research Assistant
Professor at the Casey Eye Institute, Oregon Health and Science
University.

The results of the study show that photoreceptors, the key
cells of the eye involved in vision, were protected from
degeneration following transplantation of HuCNS-SC cells into
the Royal College of Surgeons (RCS) rat. The RCS rat is a
well-established model of retinal disease which has been used
extensively to evaluate potential cell therapies. Moreover, the
number of cone photoreceptors, which are responsible for
central vision, remained constant over an extended period,
consistent with the sustained visual acuity and light
sensitivity observed in the study. In humans, degeneration of
the cone photoreceptors account for the unique pattern of
visual loss in dry AMD.

"These results are the most robust shown to date in this animal
model," said Dr. Lund, one of the study's lead investigators.
"One of the more striking findings is that the effect on vision
was long-lasting and correlated with the survival of HuCNS-SC
cells more than seven months after transplantation, which is
substantially longer than other cell types transplanted into
this same model. Also important, particularly for potential
clinical application, was that the cells spread from the site
of initial application to cover more of the retina over time.
These data suggest that HuCNS-SC cells appear to be a
well-suited candidate for cell therapy in retinal degenerative
conditions."

Alexandra Capela, Ph.D., another of the study's investigators
and a senior scientist at StemCells, commented, "This study
showed that the HuCNS-SC cells persisted and migrated
throughout the retina, with no evidence of abnormal cell
formation, which supports our hypothesis of a single transplant
therapeutic. With this research, then, we have shown that
vision can be positively impacted with a simple approach that
does not require replacing photoreceptors or the RPE cells. We
look forward to investigating this promising approach in the
clinic later this year."

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and
commercialization of cell-based therapeutics and tools for use
in stem cell-based research and drug discovery. The Company's lead
therapeutic product candidate, HuCNS-SC(R) cells (purified
human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system
disorders. Clinical trials are currently underway in spinal
cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children. In addition, the Company
plans to initiate a clinical trial of HuCNS-SC cells in the dry
form of age-related macular degeneration in 2012, and is also
pursuing preclinical studies of its HuCNS-SC cells in
Alzheimer's disease. StemCells also markets stem cell research
products, including media and reagents, under the SC Proven(R)
brand, and is developing stem cell-based assay platforms for
use in pharmaceutical research, drug discovery and drug
development. Further information about StemCells is available
at
http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this
press release constitutes forward-looking statements within the
meaning of the Securities Act of 1933, as amended, and the
Securities Exchange Act of 1934, as amended, and is subject to
the safe harbors created therein. These statements include, but
are not limited to, statements regarding the prospect of the
Company's HuCNS-SC cells to preserve vision in animal models of
retinal disease; the prospect of successful results from this
research collaboration and advancing to clinical testing in
age-related macular degeneration or other retinal disease; the
potential of the Company's HuCNS-SC cells to treat a broad
range of central nervous system disorders; the prospect and
timing associated with initiating a clinical trial in a retinal
disorder; and the future business operations of the Company,
including its ability to conduct clinical trials as well as its
other research and product development efforts. These
forward-looking statements speak only as of the date of this
news release. The Company does not undertake to update any of
these forward-looking statements to reflect events or
circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain
assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those
contemplated in such forward-looking statements due to risks
and uncertainties to which the Company is subject, including
the fact that additional trials will be required to demonstrate
the safety and efficacy of the Company's HuCNS-SC cells for the
treatment of any disease or disorder; uncertainty as to whether
the results of the Company's preclinical studies in retinal
disease will be replicated in humans; uncertainty as to whether
the FDA or other applicable regulatory agencies will permit the
Company to continue clinical testing in spinal cord injury, PMD
or in future clinical trials of proposed therapies for other
diseases or conditions given the novel and unproven nature of
the Company's technologies; uncertainties regarding the
Company's ability to recruit the patients required to conduct
its clinical trials or to obtain meaningful results;
uncertainties regarding the Company's ability to obtain the
increased capital resources needed to continue its current and
planned research and development operations; uncertainty as to
whether HuCNS-SC and any products that may be generated in the
future in the Company's cell-based programs will prove safe and
clinically effective and not cause tumors or other adverse side
effects; uncertainties regarding the Company's ability to
commercialize a therapeutic product and its ability to
successfully compete with other products on the market; and
other factors that are described under the heading "Risk
Factors" in the Company's Annual Report on Form 10-K for the
year ended December 31, 2010, and in its subsequent reports on
Forms 10-Q and 8-K.

See the original post here:
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision

Stem Cell’s in Sarasota by Regenerative clinic for Meniscus Damage. – Video

05-11-2011 09:35 http://www.GeckoJointandSpine.com Repair Meniscus injury with PRP. Platelet-rich plasma (PRP) is generically defined as an increase (above baseline) in the concentration of platelets and their associated growth factors. While the clinical benefits of PRP in enhancing the healing of musculoskeletal tissues are only beginning to be explored, the substantial amount of basic science data supporting the role of growth factors in enhancing cell migration, cell proliferation, and matrix synthesis has provided a compelling rationale for use of PRP in the treatment and repair of various connective tissue structures. In Sarasota florida now. I have asked a group of leading orthopedic surgeons who have utilized PRP in their respective practices to share their insight and experience regarding the potential role of PRP in enhancing connective tissue repair.

Read the original:
Stem Cell's in Sarasota by Regenerative clinic for Meniscus Damage. - Video

Stem Cell Financing – Video

22-01-2012 12:22 http://www.StemCellTreatment.org We offer stem cell financing to qualified candidates on many different procedures. We are the only stem cell treatment clinic that offers stem cell financing because we have had proven success with over 8000 stem cell procedures performed. If you are interested in stem cell financing then visit our website and simply fill out the form and one of our credit specialist will get back to you asap!

See the rest here:
Stem Cell Financing - Video